Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Prostatic Neoplasms × fludrocortisone acetate × Clear all

Phase

Status

Active not recruiting 2 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1 Prostate Cancer Metastatic 1 Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 51 Specimen Handling 40 enzalutamide 33 Androgen Antagonists 29 Radiosurgery 28 Radiotherapy 26 Abiraterone Acetate 24 darolutamide 21 Prednisone 21 Pluvicto 21 Docetaxel 20 apalutamide 17 Leuprolide 16 Standard of Care 15 Radiation 15 Biopsy 14 gallium 68 PSMA-11 13 Goserelin 13 Blood Specimen Collection 13 relugolix 12 abiraterone 12 Triptorelin Pamoate 12 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11 Surveys and Questionnaires 11 X-Rays 10 pembrolizumab 9 Carboplatin 9 Photons 8 Methods 8 Interviews as Topic 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06136650 2026-03-09

MK-5684-004

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡